EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors

Javier Molina-Cerrillo, Arantzazu Sierra-Ramirez, José L López-Aceituno, Marinela Méndez-Pertuz, Teresa Alonso-Gordoa, Michael Linnebacher, Matteo Santoni, Pablo J Fernandez-Marcos, Enrique Grande

Drugs in R&D · 2026-06 · 26 (2) · 155-167

DOI: 10.1007/s40268-026-00544-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in R&D, online erschienen am 24.05.2026. Verfasst von Javier Molina-Cerrillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Ramón y Cajal, 28034, Madrid, Spain. Javier.molinace@gmail.com. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Everolimus, Pyrimidines, Tryptophan Hydroxylase. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GETNE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsEverolimusPyrimidinesTryptophan HydroxylaseMTOR InhibitorsPhenylalanineAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsAnimalsHumansCell Line, TumorMiceMice, NudeApoptosisCell SurvivalXenograft Model Antitumor AssaysCell ProliferationFemale

Substanzen

EverolimusPyrimidinesTryptophan HydroxylaseMTOR InhibitorsPhenylalaninetelotristat ethylAntineoplastic Agents

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Universitario Ramón y Cajal, 28034, Madrid, Spain. Javier.molinace@gmail.com.
  • Metabolic Syndrome Group-BIOPROMET, Madrid Institute for Advanced Studies-IMDEA Food, CEI UAM+CSIC, 8, Cantoblanco Road, 28049, Madrid, Spain.
  • CNIO Cancer Center, Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario Ramón y Cajal, 28034, Madrid, Spain.
  • Department of General Surgery, Section of Molecular Oncology and Immunotherapy, University of Rostock, 18055, Rostock, Germany.
  • Medical Oncology Unit, Macerata Hospital, Macerata, Italy.

Förderung

  • GETNE

Zitieren

APA

Molina-Cerrillo, J., Sierra-Ramirez, A., López-Aceituno, J. L., Méndez-Pertuz, M., Alonso-Gordoa, T., Linnebacher, M., Santoni, M., Fernandez-Marcos, P. J., & Grande, E. (2026). A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors. Drugs in R&D, 26(2), 155-167. https://doi.org/10.1007/s40268-026-00544-x

Vancouver

Molina-Cerrillo J, Sierra-Ramirez A, López-Aceituno JL, Méndez-Pertuz M, Alonso-Gordoa T, Linnebacher M, et al. A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors. Drugs in R&D. 2026;26(2):155-167. doi:10.1007/s40268-026-00544-x

BibTeX
@article{MolinaCerrillo2026,
  author = {Molina-Cerrillo, Javier and Sierra-Ramirez, Arantzazu and López-Aceituno, José L and Méndez-Pertuz, Marinela and Alonso-Gordoa, Teresa and Linnebacher, Michael and Santoni, Matteo and Fernandez-Marcos, Pablo J and Grande, Enrique},
  title = {A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors},
  journal = {Drugs in R&D},
  year = {2026},
  volume = {26},
  number = {2},
  pages = {155--167},
  doi = {10.1007/s40268-026-00544-x}
}
Kostenlos starten →